Conversion therapy extends survival for locally advanced intrahepatic cholangiocarcinoma patients

Conversion therapy (CT) significantly improves overall and progression-free survival in patients with locally advanced intrahepatic cholangiocarcinoma (LA-ICCA). In a retrospective analysis of 115 patients, median overall survival reached 45.53 months and progression-free survival was 18.23 months post-propensity score matching, both superior to systemic therapy (ST) outcomes. CT emerged as an independent factor linked to better results, indicating its potential as a transformative approach in treating this aggressive malignancy.